DENTSPLY SIRONA INC (XRAY)
US24906P1093 - Common Stock
Taking everything into account, XRAY scores 4 out of 10 in our fundamental rating. XRAY was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While XRAY is still in line with the averages on profitability rating, there are concerns on its financial health. XRAY has a bad growth rate and is valued cheaply. XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
XRAY had positive earnings in the past year.
In the past year XRAY had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: XRAY reported negative net income in multiple years.
XRAY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
XRAY's Return On Assets of -6.23% is fine compared to the rest of the industry. XRAY outperforms 62.57% of its industry peers.
Looking at the Return On Equity, with a value of -16.58%, XRAY is in the better half of the industry, outperforming 62.03% of the companies in the same industry.
XRAY's Return On Invested Capital of 4.09% is fine compared to the rest of the industry. XRAY outperforms 75.40% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for XRAY is below the industry average of 8.23%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.23% | ||
| ROE | -16.58% | ||
| ROIC | 4.09% |
ROA(3y)-3.26%
ROA(5y)-1.52%
ROE(3y)-6.9%
ROE(5y)-3.43%
ROIC(3y)4.86%
ROIC(5y)4.47%
1.3 Margins
XRAY has a Operating Margin of 6.74%. This is in the better half of the industry: XRAY outperforms 73.26% of its industry peers.
In the last couple of years the Operating Margin of XRAY has declined.
XRAY has a Gross Margin (52.18%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.74% | ||
| PM (TTM) | N/A | ||
| GM | 52.18% |
OM growth 3Y-3.46%
OM growth 5Y-3.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.16%
GM growth 5Y0.32%
2. Health
2.1 Basic Checks
XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
XRAY has less shares outstanding than it did 1 year ago.
The number of shares outstanding for XRAY has been reduced compared to 5 years ago.
Compared to 1 year ago, XRAY has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.25, we must say that XRAY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XRAY (1.25) is comparable to the rest of the industry.
The Debt to FCF ratio of XRAY is 6.07, which is on the high side as it means it would take XRAY, 6.07 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 6.07, XRAY is doing good in the industry, outperforming 76.47% of the companies in the same industry.
XRAY has a Debt/Equity ratio of 0.72. This is a neutral value indicating XRAY is somewhat dependend on debt financing.
XRAY has a Debt to Equity ratio of 0.72. This is in the lower half of the industry: XRAY underperforms 72.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 6.07 | ||
| Altman-Z | 1.25 |
ROIC/WACC0.49
WACC8.3%
2.3 Liquidity
XRAY has a Current Ratio of 1.25. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.25, XRAY is not doing good in the industry: 85.56% of the companies in the same industry are doing better.
A Quick Ratio of 0.84 indicates that XRAY may have some problems paying its short term obligations.
XRAY's Quick ratio of 0.84 is on the low side compared to the rest of the industry. XRAY is outperformed by 87.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
The earnings per share for XRAY have decreased by 0.00% in the last year.
The Earnings Per Share has been decreasing by -1.86% on average over the past years.
XRAY shows a decrease in Revenue. In the last year, the revenue decreased by -0.91%.
The Revenue has been decreasing by -0.11% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y0.74%
EPS 5Y-1.86%
EPS Q2Q%2.04%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y5.9%
Revenue growth 5Y-0.11%
Sales Q2Q%0.42%
3.2 Future
XRAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.30% yearly.
XRAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.88% yearly.
EPS Next Y7.06%
EPS Next 2Y6.16%
EPS Next 3Y9.95%
EPS Next 5Y14.3%
Revenue Next Year-2.35%
Revenue Next 2Y-1.51%
Revenue Next 3Y0.08%
Revenue Next 5Y3.88%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.01, which indicates a very decent valuation of XRAY.
Based on the Price/Earnings ratio, XRAY is valued cheaply inside the industry as 96.79% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of XRAY to the average of the S&P500 Index (28.65), we can say XRAY is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.98, the valuation of XRAY can be described as reasonable.
Based on the Price/Forward Earnings ratio, XRAY is valued cheaper than 98.40% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.56, XRAY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.01 | ||
| Fwd PE | 8.98 |
4.2 Price Multiples
XRAY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XRAY is cheaper than 95.72% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, XRAY is valued cheaper than 96.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.29 | ||
| EV/EBITDA | 9.32 |
4.3 Compensation for Growth
XRAY's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.42
PEG (5Y)N/A
EPS Next 2Y6.16%
EPS Next 3Y9.95%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.58%, XRAY has a reasonable but not impressive dividend return.
In the last 3 months the price of XRAY has falen by -26.83%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 1.68, XRAY pays a better dividend. On top of this XRAY pays more dividend than 98.93% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.23, XRAY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.58% |
5.2 History
The dividend of XRAY is nicely growing with an annual growth rate of 9.48%!
XRAY has paid a dividend for at least 10 years, which is a reliable track record.
XRAY has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)9.48%
Div Incr Years5
Div Non Decr Years29
5.3 Sustainability
XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
The dividend of XRAY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP-30.27%
EPS Next 2Y6.16%
EPS Next 3Y9.95%
DENTSPLY SIRONA INC
NASDAQ:XRAY (11/20/2024, 8:00:02 PM)
After market: 18.52 0 (0%)18.52
-0.36 (-1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.75B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.58% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.01 | ||
| Fwd PE | 8.98 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.42
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.23% | ||
| ROE | -16.58% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 6.74% | ||
| PM (TTM) | N/A | ||
| GM | 52.18% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.25 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y0.74%
EPS 5Y
EPS Q2Q%
EPS Next Y7.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y5.9%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y